title: An update on the Diabetes Prevention Program.
abstract: OBJECTIVE
  To summarize the results of the Diabetes Prevention Program (DPP) and describe the additional 5-year follow-up study.
  
  
  METHODS
  The design, implementation, and outcome of the DPP are reviewed, and an economic analysis of the effects of diabetes prevention and delay is presented.
  
  
  RESULTS
  The DPP, thus far the largest diabetes prevention trial with the most ethnically diverse patient population, originally consisted of more than 3,800 subjects with impaired glucose tolerance. These subjects were randomized to receive one of four interventions: intensive lifestyle adjustments or standard lifestyle plus one of the following--placebo, metformin, or troglitazone. In June 1998, the troglitazone treatment was discontinued after a fatal case of liver failure in a study participant, but the subjects in this arm of the study continued to undergo followup. Thus, 3,234 subjects remained in the other three arms of the study. After a mean of 2.8 years of follow-up, the DPP was prematurely terminated because of an observed significant benefit to the intervention groups. Both metformin therapy and intensive lifestyle intervention reduced the risk of developing diabetes (by 31% and 58%, respectively, in comparison with placebo), and both interventions were deemed to be cost-effective on the basis of computer projections over a lifetime. Because of the premature discontinuation of the DPP, the durability of the interventions on diabetes prevention and the effect on microvascular and macrovascular disease could not be assessed. The subsequent outcomes study will address these issues during a 5-year follow-up period.
  
  
  CONCLUSIONS
  The DPP showed that both metformin and intensive lifestyle modifications effectively delayed or prevented the development of diabetes in a cost-effective manner.
authors.affiliation: MedStar Research Institute, Hyattsville, Maryland, USA.
authors.forename: Robert E
authors.initials: RE
authors.lastname: Ratner
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002839:Chromans / Q000008:administration & dosage; D003920:Diabetes Mellitus / Q000191:economics / Q000517:prevention & control*; D005006:Ethnicity; D015444:Exercise; D018149:Glucose Intolerance / Q000628:therapy; D017048:Health Care Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D008019:Life Style; D008687:Metformin / Q000008:administration & dosage; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009316:National Institutes of Health (U.S.); D009765:Obesity / Q000150:complications; D010349:Patient Compliance; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D045162:Thiazolidinediones / Q000008:administration & dosage; D000077288:Troglitazone; D014481:United States; D015431:Weight Loss
chemical_list: D002839:Chromans; D007004:Hypoglycemic Agents; D010919:Placebos; D045162:Thiazolidinediones; D008687:Metformin; D000077288:Troglitazone